Results 11 to 20 of about 898 (115)

Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy [PDF]

Kidney International Reports
Introduction: C3 glomerulopathy (C3G) is a complex, chronic, ultra rare, progressive primary glomerulonephritis, resulting from alternative complement pathway overactivation, leading to kidney failure in most patients, and frequent recurrence in ...
Manuel Praga, Moglie le Quintrec, Guido Junge   +2 more
exaly   +11 more sources

A Practical Method for Synthesizing Iptacopan

Molecules
Iptacopan, the first orally available small-molecule complement factor B inhibitor, was developed by Novartis AG of Switzerland. Iptacopan for the treatment of PNH was just approved by the FDA in December 2023.
Shao-Xin Chen
exaly   +4 more sources

Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria [PDF]

Терапевтический архив
Aim. To evaluate the hematological response within 4 weeks of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to long-term eculizumab therapy. Materials and methods.
Olesya U. Klimova, Irina K. Golubovskaya, Yuriy N. Kuznetsov, Maria V. Marchenko, Alexander D. Kulagin   +4 more
doaj   +2 more sources

Successful switch from pegcetacoplan to iptacopan after repeated severe breakthrough hemolysis events – case report

Hematology
Objectives A subset of paroxysmal nocturnal hemoglobinuria (PNH) patients develops clinically relevant extravascular hemolysis when treated with complement C5 inhibitors.
Wolfgang Füreder, Andreas Reinisch
doaj   +2 more sources

Assessment of QT Interval Prolongation Using Concentration–QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals [PDF]

Clinical and Translational Science
To assess cardiac and safety parameters of iptacopan (an oral, selective, reversible, small‐molecule factor B inhibitor), we conducted a phase I, single ascending dose (SAD), exposure–response study (A2107) instead of a traditional thorough QT study ...
Noemi Kaetterer, Kenneth Kulmatycki, Prasanna Kumar Nidamarthy, Elizabeth McNamara, Danielle Armas, Venkateswar Jarugula, Robert Schmouder   +6 more
doaj   +2 more sources

Case report: Sequential complement inhibition and BAFF/APRIL blockade in progressive IgA nephropathy and IgA vasculitis nephritis: a report of two cases [PDF]

Frontiers in Immunology
Rapidly progressive IgA nephropathy (IgAN) and IgA vasculitis nephritis (IgAVN) are characterized by marked glomerular inflammation, extensive extracapillary proliferation, and rapid renal function decline.
Xinyuan Tian, Xinyuan Tian, Xinyuan Tian, Xinyuan Tian, Wanyin Hou, Wanyin Hou, Wanyin Hou, Wanyin Hou, Xiaojuan Yu, Xiaojuan Yu, Xiaojuan Yu, Xiaojuan Yu, Lei Jiang, Lei Jiang, Lei Jiang, Lei Jiang, Xin Zhang, Xin Zhang, Xin Zhang, Xin Zhang, Xu Zhang, Suxia Wang, Ying Tan, Ying Tan, Ying Tan, Ying Tan, Lijun Liu, Lijun Liu, Lijun Liu, Lijun Liu   +29 more
doaj   +2 more sources

Early Experience With Iptacopan for Recurrent IgA Nephropathy After Kidney Transplantation [PDF]

Kidney Medicine
Immunoglobulin A (IgA) nephropathy is a common cause of kidney failure and can recur after kidney transplantation, increasing the risk of allograft loss.
Ayman Al Jurdi, Abraham Cohen Bucay, Pitchaphon Nissaisorakarn, Hannah Gilligan, Claire T. Avillach, Veronica E. Klepeis, Rex N. Smith, Ragnar Palsson, Kassem Safa, Leonardo V. Riella   +9 more
doaj   +2 more sources

Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment [PDF]

Journal of Comparative Effectiveness Research
This study conducted an indirect treatment comparison (ITC) of iptacopan, the first oral monotherapy targeting factor B, versus pegcetacoplan, a subcutaneous infusion targeting complement component 3, in patients with paroxysmal nocturnal ...
Austin Kulasekararaj, Phillip Scheinberg, Maria-Magdalena Balp, Olivier Somenzi, Anggie Wiyani, Josefin Snellman, Sarah Walsh, Katharina Pannagl, Jason Steenkamp, Régis Peffault de Latour   +9 more
doaj   +2 more sources

Reshaping the therapeutic landscape of IgA nephropathy: a Bayesian network meta-analysis on the comparative efficacy and safety of immunosuppressants and targeted agents [PDF]

BMC Nephrology
Background Comparative evidence between conventional immunosuppressants and emerging targeted therapies for IgA nephropathy (IgAN) is limited by a lack of head-to-head trials.
Rulong Chen, Jinxin Zhang, Jiating Chen, Tingfei Xie, Yunpeng Xu, Zhaoyong Hu, Jihong Chen   +6 more
doaj   +2 more sources

Iptacopan in Idiopathic Immune Complex–Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study

Kidney International Reports
Introduction: Immune complex–mediated membranoproliferative glomerulonephritis (IC-MPGN) is an ultra-rare, fast-progressing kidney disease that may be idiopathic (primary) or secondary to chronic infection, autoimmune disorders, or monoclonal ...
Andrew Bomback, Marina Vivarelli, Richard Smith   +2 more
exaly   +3 more sources